Your Health, We Care
Release date: 2026-02-12 17:54:00 Recommended: 10
Selpercatinib is a National Comprehensive Cancer Network (NCCN) recommended treatment option for certain types of RET-positive metastatic non-small cell lung cancer (NSCLC) and RET-positive advanced or metastatic thyroid cancer.
Selpercatinib is used to treat certain cancers caused by abnormal RET genes. It is indicated for:
Adults with locally advanced non-small cell lung cancer (NSCLC) or NSCLC that has spread.
Adults and children aged 2 years and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who require oral or injectable medication (systemic therapy).
Adults and children aged 2 years and older with advanced thyroid cancer or thyroid cancer that has spread, who require oral or injectable medication (systemic therapy) and have received radioactive iodine therapy that did not work or is no longer effective.
Adults and children aged 2 years and older with locally advanced solid tumors or solid tumors that have spread, whose disease has worsened (progressed) during or after other treatments, or who have no satisfactory treatment options.
Your doctor will perform tests to ensure Selpercatinib is suitable for you.
For children under 2 years of age, the safety and effectiveness of Selpercatinib in the following treatments are not known:
Advanced MTC or MTC that has spread, requiring oral or injectable medication.
Advanced thyroid cancer or thyroid cancer that has spread, requiring oral or injectable medication, and who have received radioactive iodine therapy that did not work or is no longer effective.
Locally advanced solid tumors or solid tumors that have spread, which have worsened during or after other treatments, or for which there are no satisfactory treatment options.
If you are able to become pregnant:
Your doctor will perform a pregnancy test before you start treatment with Selpercatinib.
You should use effective contraception during treatment and for 1 week after your last dose of Selpercatinib.
Consult your doctor about which contraceptive methods may be suitable for you.
If you become pregnant or suspect you may be pregnant during treatment with Selpercatinib, tell your doctor immediately.
Males with partners who can become pregnant should use effective contraception during treatment with Lucius Pharmaceuticals Selpercatinib and for 1 week after the last dose.
These are not all the possible side effects of Selpercatinib. If you are concerned about side effects, consult your doctor. Tell your doctor about any side effects you experience.
Before taking Lucius Pharmaceuticals Selpercatinib, inform your doctor of all your medical conditions, including whether you:
Have liver problems;
Have lung or breathing problems (not related to lung cancer);
Have high blood pressure;
Have heart problems, including a condition called QT prolongation;
Have bleeding problems;
Are planning to undergo surgery: You should stop taking Selpercatinib at least 7 days before scheduled surgery.
Are breastfeeding or planning to breastfeed: It is not known whether Selpercatinib passes into your breast milk. Do not breastfeed during treatment with Selpercatinib and for 1 week after your last dose.
Additionally, tell your doctor about all the medications you are taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Selpercatinib may affect how other medications work, and other medications may affect how Selpercatinib works, potentially increasing your risk of side effects.
